Supported by unrestricted education grants from Alcon Vision, Johnson & Johnson Vision, and Orasis Pharmaceuticals.
Upon completion of this activity, the participant should be able to:
a. Define the ideal pre-cataract presbyopia patient for pharmacological treatment, including prevalence, age ranges, refractive error levels, key demographics, and other clinical and socioeconomic parameters
b. Determine ideal practices for identifying and diagnosing pre-cataract presbyopic patients
c. Compare and contrast the advantages and disadvantages of the various mechanisms of action for different pharmacological presbyopia treatments, including efficacy, safety, and functionality
d. Describe ideal practice protocols for treating pre-cataract presbyopia patients with medical therapies
Jointly Provided by Evolve Medical Education and The Fundingsland Group
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Evolve Medical Education, LLC, and The Fundingsland Group. Evolve Medical Education, LLC is accredited by the ACCME to provide continuing medical education for physicians.
Designation Statement
Evolve Medical Education, LLC designates this enduring material for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 11 for Windows
Edge (recent versions; Chromium-based) for Windows
Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Safari (recent versions) for Mac OSX, or iOS
Hardware Requirements:
4GB+ RAM
Recommended internet speed 5Mbps+
Edward J. Holland, MD
Professor of Ophthalmology
University of Cincinnati
Director, Cornea Service
Cincinnati Eye Institute
Cincinnati, Ohio
Marjan Farid, MD
Director of Cornea, Cataract, and Refractive Surgery
Vice Chair of Ophthalmic Faculty
Clinical Professor of Ophthalmology
Gavin Herbert Eye Institute
University of California, Irvine
Nicole Fram, MD
Managing Partner at Advanced Vision Care in Los Angeles, CA
Clinical Instructor of Ophthalmology
Stein Eye Institute
University of California,Los Angeles
Edward J. Holland, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Abingworth, Aerie Pharmaceuticals, Akros Pharma, Alcon Vision, Aldeyra Therapeutics, Allegro, Allergan, Azura Ophthalmics, BlephEx, BRIM biotech, Carl Zeiss Medtec, Claris Bio, Corneat, CorneaGen, Dompé, Expert Opinion, EyePoint Pharmaceuticals, Glaukos, Hanall, Invirsa, Kala Pharmaceuticals, Mati Therapeutics, Merck, Novartis Pharmaceuticals, Ocular Therapeutix, Ocuphire, Omeros, Oyster Point Pharma, Precise Bio, Prometic Biotherapeutics, ReGentree, Retear, Senju, Shire, Sight Sciences, Slack, Tarsus RX, TearLab, Vomaris, and W.L. Gore and Associates. Speaker’s List: Alcon Vision, Novartis Pharmaceuticals, Omeros, Senju, and Shire. Other Financial/Material Support: Alcon Vision, Mati Therapeutics, Novartis Pharmaceuticals, Omeros, Senju, and Shire.
Marjan Farid, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, BioTissue, Carl Zeiss Meditec, CorneaGen, Dompé, Eyepoint Pharmaceuticals, Eyevance, Johnson & Johnson Vision, Kala Pharmaceuticals, and Novartis.
Nicole Fram, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon Vision, Allergan, CorneaGen, Johnson & Johnson Vision, and Ocular Therapeutics. Grant/Research Support: Alcon Vision, and Allergan. Speaker’s List: Alcon Vision, BVI, CorneaGen, Dompé, MST, and Ocular Therapeutix. Stock/Shareholder: CorneaGen, and Ocular Science.
Faculty:
Edward J. Holland, MD
Moderator
Director of Cornea Services, Cincinnati Eye Institute
Professor of Clinical Ophthalmology, University of Cincinnati
Cincinnati, Ohio
Nicole Fram, MD
Managing Partner at Advanced Vision Care in Los Angeles, CA
Clinical Instructor of Ophthalmology at the Stein Eye Institute, UCLA
Los Angeles, California
Marjan Farid, MD
Director of Cornea, Cataract, and Refractive Surgery, Vice Chair of Ophthalmic Faculty, and Clinical Professor of Ophthalmology, Gavin Herbert Eye Institute, University of California, Irvine
Irvine, California
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.
The following faculty/staff members have the following financial relationships with commercial interests:
Marjan Farid, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, Bio-Tissue, Carl Zeiss Meditec, Corneagen, Dompe, Eyepoint, Eyevance, Johnson & Johnson Vision, Kala, and Novartis.
Nicole R. Fram, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon, Allergan, CorneaGen, Johnson & Johnson Vision, and Ocular Therapeutics. Grant/Research Support: Alcon, and Allergan. Speaker’s Bureau: Alcon, BVI, CorneaGen, Dompe, MST, and Ocular Therapeutix. Stock/Shareholder: CorneaGen, and Ocular Science.
Edward J. Holland, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Abingworth, Aerie Pharmaceuticals, Akros Pharma, Inc., Alcon, Aldeyra Therapeutics, Allegro, Allergan, Azura Ophthalmics, BlephEx, LLC, BRIM biotech, Claris Bio, Corneat, CorneaGen, Expert Opinion, Dompe, EyePoint, Glaukos Corporation, Hanall, Invirsa, Kala Pharmaceuticals, Mati Therapeutics, Merck KGgA, Novartis NIBR, Novartis Pharmaceuticals, Ocular Therapeutix, Ocuphire, Omeros Corporation, OysterPoint, Precise Bio, Prometic Biotherapeutics, ReGentree, LLC, Retear, Senju, Shire, Sight Sciences, Slack, Inc., Tarsus RX, TearLab Research, Inc., Vomaris, W.L. Gore and Associates, and Zeiss. Speakers Bureau: Alcon, Novartis Pharmaceticals, Omeros Corporation, Senju, and Shire. Other Financial Support: Alcon, Mati Therapeutics, Novartis Pharmaceuticals, Omeros Corporation, Senju, and Shire.
The Evolve Medical Education and The Fundingsland Group staff and planners have no financial relationships with commercial interests.
Nisha Mukherjee, MD, peer reviewer, has no financial relationships with commercial interests.
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, The Fundingsland Group, or Alcon Vision, Johnson & Johnson Vision, and Orasis Pharmaceuticals.
